Statera Biopharma, Inc. entered a Binding Memorandum of Understanding to acquire 25% in Holobeam Technologies, Inc. for $25 million on October 12, 2022. The consideration will be paid via the issuance of the Company's preferred stock or a combination of preferred stock and cash. The Transaction is subject to availability of at least $10 million on the balance sheet of the Statera Biopharma at the close of the Transaction, approval by a majority of HOLO's stockholders and approval by board of directors of Statera Biopharma, receipt of a fairness opinion by HOLO from an investment bank of its choosing and other customary conditions.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | 0.00% | 0.00% | +16.67% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 50.81K | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- STAB Stock
- News Statera Biopharma, Inc.
- Statera Biopharma, Inc. entered a Binding Memorandum of Understanding to acquire 25% in Holobeam Technologies, Inc. for $25 million.